Charles River Laboratories International, Inc.

Healthcare · Medical - Diagnostics & Research

Overall research band Mixed

Quality Weak

Valuation Mixed

Balance sheet Very weak

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Charles River Laboratories International, Inc. is a contract research organization that provides essential preclinical services to the pharmaceutical and biotechnology industries worldwide. The company operates through three main segments: Research Models and Services (RMS), which supplies high-quality rodent research models and related support services; Discovery and Safety Assessment (DSA), offering early-phase discovery and safety testing such as toxicology, pathology, and pharmacokinetics; and Manufacturing Solutions, which delivers in vitro quality control testing, biologics testing, and avian vaccine services. Its customers include pharmaceutical and biotechnology companies seeking assistance with drug discovery, non-clinical development, and safety testing. Charles River generates revenue by offering these specialized research models, laboratory services, and quality control solutions to clients globally.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC6.7%Model input; read with the evidence status and period context.

Operating margin12.6%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years3.2%Model input; read with the evidence status and period context.

FCF margin12.9%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.